» Articles » PMID: 33442731

PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain

Abstract

Acetylcholine (ACh) has distinct functional roles in striatum compared with cortex, and imbalance between these systems may contribute to neuropsychiatric disease. Preclinical studies indicate markedly higher ACh concentrations in the striatum. The goal of this work was to leverage positron emission tomography (PET) imaging estimates of drug occupancy at cholinergic receptors to explore ACh variation across the human brain, because these measures can be influenced by competition with endogenous neurotransmitter. PET scans were analyzed from healthy human volunteers (n = 4) and nonhuman primates (n = 2) scanned with the M1-selective radiotracer [11C]LSN3172176 in the presence of muscarinic antagonist scopolamine, and human volunteers (n = 10) scanned with the α4β2* nicotinic ligand (-)-[18F]flubatine during nicotine challenge. In all cases, occupancy estimates within striatal regions were consistently lower (M1/scopolamine human scans, 31 ± 3.4% occupancy in striatum, 43 ± 2.9% in extrastriatal regions, p = 0.0094; nonhuman primate scans, 42 ± 26% vs. 69 ± 28%, p < 0.0001; α4β2*/nicotine scans, 67 ± 15% vs. 74 ± 16%, p = 0.0065), indicating higher striatal ACh concentration. Subject-level measures of these concentration differences were estimated, and whole-brain images of regional ACh concentration gradients were generated. These results constitute the first in vivo estimates of regional variation in ACh concentration in the living brain and offer a novel experimental method to assess potential ACh imbalances in clinical populations.

Citing Articles

Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.

Zhang J, Fu H, Lin R, Zhou J, Haider A, Fang W J Med Chem. 2023; 66(16):10889-10916.

PMID: 37583063 PMC: 10461233. DOI: 10.1021/acs.jmedchem.3c00573.


Cholinergic system adaptations are associated with cognitive function in people recently abstinent from smoking: a (-)-[F]flubatine PET study.

Calakos K, Hillmer A, Anderson J, LeVasseur B, Baldassarri S, Angarita G Neuropsychopharmacology. 2023; 48(4):683-689.

PMID: 36681758 PMC: 9938267. DOI: 10.1038/s41386-023-01535-1.

References
1.
Quick M, Lester R . Desensitization of neuronal nicotinic receptors. J Neurobiol. 2002; 53(4):457-78. DOI: 10.1002/neu.10109. View

2.
Calabresi P, Picconi B, Parnetti L, Di Filippo M . A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 2006; 5(11):974-83. DOI: 10.1016/S1474-4422(06)70600-7. View

3.
Cunningham V, Rabiner E, Slifstein M, Laruelle M, Gunn R . Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2009; 30(1):46-50. PMC: 2949110. DOI: 10.1038/jcbfm.2009.190. View

4.
Picciotto M, Lewis A, van Schalkwyk G, Mineur Y . Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology. 2015; 96(Pt B):235-43. PMC: 4486625. DOI: 10.1016/j.neuropharm.2014.12.028. View

5.
Farde L, Nordstrom A, Wiesel F, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49(7):538-44. DOI: 10.1001/archpsyc.1992.01820070032005. View